Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519098 | 1.00 | GABRA5 (0.48) | GABRA5PARP15PARP10PARP2NR1H4 | |
| SCHEMBL5532800 | 0.89 | GABRA5 (0.46) | GABRA5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5532805 | 0.89 | GABRA5 (0.46) | GABRA5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5521806 | 0.85 | HDAC3 (0.51) | PARP15PARP10PARP2NR1H4HDAC3 | |
| SCHEMBL5521812 | 0.85 | HDAC3 (0.51) | PARP15PARP10PARP2NR1H4HDAC3 | |
| SCHEMBL5523321 | 0.85 | HDAC3 (0.51) | PARP15PARP10PARP2NR1H4HDAC3 | |
| SCHEMBL5525010 | 0.82 | ACACB (0.48) | — | |
| SCHEMBL5525008 | 0.82 | ACACB (0.48) | — | |
| SCHEMBL12020459 | 0.81 | GABRA5 (0.52) | GABRA5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5526237 | 0.80 | CXCR3 (0.54) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | GABRA5 35/4885PARP15 3115/4885PARP10 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.